Host your events on tradezing app
COMMUNITY AUDIO ROOMS
No available audio rooms
Upcoming Events
Why You Should Do Business With Multiple Banks For Different Reasons
1 Day20 Hr42 Min3 Sec
TradeZing
Get the TradeZing Newsletter
Latest Feed
October 04
4:00 pm
18 mins ago
What Are Your Moves Tomorrow, October 05, 2023
**Join [WSB’s community voice chat](https://discord.com/channels/1037784194476163223/1083096862099263528), every day from 8:30am to whenever!** Check out our [Earnings Thread](https://reddit.com/r/wallstreetbets/comments/16qacay/most_anticipated_earnings_releases_for_the_week/) and [Rules](https://www.reddit.com/r/wallstreetbets/wiki/contentguide). DM the [mod inbox](https://www.reddit.com/message/compose/?to=/r/wallstreetbets)
October 04
4:00 pm
18 mins ago
Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 – 15, 2023.
October 04
3:55 pm
23 mins ago
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on September 28, 2023, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below $1.00 per share for 30 consecutive business days. The notification letter does not result in the immediate delisting of the Company’s Ordinary Shares and has no current immediate effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq.
Zelenskiy: Russia Is Using Food Prices as a Weapon
September 19, 2023
2 weeks ago
Ukraine’s President Volodymyr Zelenskiy accused Russia of turning food, energy and even people into weapons of its war, and …
Related Events
No related events associated to this feed.
Latest Feed
October 04
4:00 pm
18 mins ago
What Are Your Moves Tomorrow, October 05, 2023
**Join [WSB’s community voice chat](https://discord.com/channels/1037784194476163223/1083096862099263528), every day from 8:30am to whenever!** Check out our [Earnings Thread](https://reddit.com/r/wallstreetbets/comments/16qacay/most_anticipated_earnings_releases_for_the_week/) and [Rules](https://www.reddit.com/r/wallstreetbets/wiki/contentguide). DM the [mod inbox](https://www.reddit.com/message/compose/?to=/r/wallstreetbets)
October 04
4:00 pm
18 mins ago
Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 – 15, 2023.
October 04
3:55 pm
23 mins ago
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on September 28, 2023, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below $1.00 per share for 30 consecutive business days. The notification letter does not result in the immediate delisting of the Company’s Ordinary Shares and has no current immediate effect on the listing or trading of the Company’s Ordinary Shares on Nasdaq.
Sign up or Log in to Comment